Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24636728 | 0.87 | TBXAS1 (0.47) | NAPRTCYP19A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30706206 | 0.87 | TBXAS1 (0.47) | NAPRTCYP19A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13196040 | 0.87 | CYP3A4 (0.52) | NAPRTCYP19A1CYP17A1CYP1A2CYP3A4 | |
| SCHEMBL31226087 | 0.85 | WNT3A (0.49) | CYP19A1CYP17A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1491215 | 0.82 | CYP19A1 (0.48) | NAPRTCYP19A1CYP17A1ALDH1A1MAPK1 | |
| SCHEMBL2450503 | 0.81 | KMT2A (0.57) | ALDH1A1MAPK1TSHRKMT2A | |
| SCHEMBL9003061 | 0.81 | RECQL (0.54) | CYP1A2CYP3A4CYP2C9ALDH1A1GAA | |
| SCHEMBL19658177 | 0.80 | KMT2A (0.50) | ALDH1A1MAPK1KMT2APOLB | |
| SCHEMBL499428 | 0.79 | KMT2A (0.46) | ALDH1A1MAPK1TSHRKMT2A | |
| SCHEMBL29538625 | 0.79 | DPP4 (0.43) | NAPRTCYP19A1CYP17A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371514-B2 | Serial derivatization of peptides for de novo sequencing using tandem mass spectrometry | AGILENT TECHNOLOGIES, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1117685-B1 | TREATMENT OF INFLAMMATORY DISEASE | KING S COLLEGE LONDON (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-20060229234-A1 | Peptide factor | STEVENSON ROBERT D | 2006-10-12 | — | — | US | disclosed |
| US-6995240-B1 | Treatment of inflammatory disease | KING'S COLLEGE LONDON (GB) | 2006-02-07 | — | — | US | disclosed |
| US-20060014293-A1 | Lock mass ions for use with derivatized peptides for de novo sequencing using tandem mass spectrometry | AGILENT TECHNOLOGIES, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060014210-A1 | Serial derivatization of peptides for de novo sequencing using tandem mass spectrometry | AGILENT TECHNOLOGIES, INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1617224-A1 | De novo sequencing using tandem mass spectrometry | Agilent Technologies, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1617223-A2 | Serial derivatization of peptides for \"de Novo\" sequencing using tandem mass spectrometry | Agilent Technologies, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040213772-A1 | Peptide factor | STEVENSON ROBERT DUNCAN | 2004-10-28 | — | — | US | disclosed |
| WO-2003104813-A2 | CHARACTERISING POLYPEPTIDES | XZILLION GMBH & CO. KG (DE) | 2003-12-18 | — | — | WO | disclosed |
| US-6602519-B1 | Peptide factor used as replacement to steroid therapy; neutrophil migration stimulating activity; treating conditions associated with an inflammatory response of septic shock | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-1094833-B1 | OXIDIZED THYMOSIN BETA 4 | UNIV GLASGOW (GB) | 2003-02-12 | — | — | EP | disclosed |
| EP-1117685-A1 | TREATMENT OF INFLAMMATORY DISEASE | KINGS COLLEGE LONDON (GB) | 2001-07-25 | — | — | EP | disclosed |
| EP-1094833-A2 | OXIDIZED THYMOSIN BETA 4 | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000021995-A1 | TREATMENT OF INFLAMMATORY DISEASE | KING'S COLLEGE LONDON (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999049883-A2 | OXIDIZED THYMOSIN BETA 4 | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014210-A1 | Serial derivatization of peptides for de novo sequencing using tandem mass spectrometry | PTMS, DNPEP, SRMS | NAPRT 3258/4885CYP19A1 3249/4885CYP17A1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.